Rivasa

Quick links to important sections

Rivasa

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rivasa

What is Rivasa? An Essential Overview

This section defines the core identity, composition, and general utility of the pharmaceutical agent Rivasa, adhering strictly to its established classification and functional properties.

Property Description
Active ingredient Acetylsalicylic Acid (Aspirin)
Form Oral Tablet (typically enteric-coated)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID) and Antiplatelet Agent
Common use Pain and fever relief, and thrombosis prophylaxis
Origin Synthetic

Defining Rivasa and Its Core Active Ingredient

Rivasa is a pharmaceutical preparation that contains the single active ingredient Acetylsalicylic Acid (Aspirin), a compound that is synthetically manufactured and widely utilized. The product is typically presented as an oral tablet for ingestion, often formulated with an enteric coating. This specialized dosage feature, utilized for managing gastrointestinal tolerability, is designed to help the compound pass through the acidic stomach environment, ensuring dissolution primarily in the less caustic small intestine.


Rivasa's Dual Pharmacological Classification

Rivasa belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, but its active ingredient is uniquely also classified as a Platelet Aggregation Inhibitor. This dual classification is a key differentiating factor within the broader NSAID category. While it shares the general anti-inflammatory characteristics of its class, the specific mechanism of Acetylsalicylic Acid causes an irreversible inhibition of certain enzymes in platelets, a property that forms the basis of its specialized utility in preventing clotting. This pharmacological profile accounts for the compound's multi-purpose use.


General Purpose and Action Principle

The general purpose of Rivasa is twofold: to help relieve minor to moderate pain and reduce fever, and to provide an anti-clotting effect for smoother blood flow. The action principle involves intervening in the body's signaling pathways by blocking the synthesis of chemical messengers that generate pain, inflammation, and fever signals. This targeted inhibition allows the medicine to achieve its general utility in alleviating discomfort and supporting the maintenance of unobstructed blood flow due to its specific effect on platelet function.

Regulatory References

  1. Aspirin Monograph

What side effects are possible with Rivasa?

Possible Side Effects and Safety Information

Rivasa’s safety profile, as documented in official government regulatory documents, centers primarily on the risk of bleeding and gastrointestinal adverse events.

Adverse Reaction Categories

Bleeding is considered a serious and common adverse reaction, ranging from minor bruising to severe internal hemorrhage, including gastrointestinal bleeding and hemorrhagic stroke. This risk is due to the drug’s antiplatelet properties.

Gastrointestinal disorders are frequently reported, which may include nausea, vomiting, heartburn, abdominal pain, and stomach ulcers. Long-term or daily use is associated with an increased risk of severe stomach bleeding. Signs of serious gastrointestinal bleeding include black, tarry, or bloody stools, or vomiting blood.

Other adverse reactions that have been documented are classified within the System-Organ Classes of the Immune and Respiratory systems (e.g., hypersensitivity and asthmatic reactions) and the Nervous System (e.g., ringing in the ears).

Safety Restrictions and Warnings

Serious safety warnings in the official labeling relate to stomach bleeding and the drug being an NSAID. The risk of bleeding may be increased in older patients or those who consume three or more alcoholic drinks daily.

Contraindications define populations that should not use this medicine. These restrictions include, but are not limited to, patients with a known allergy to aspirin or other NSAIDs, those with an active stomach ulcer or a history of ulcers, a hemorrhagic diathesis (bleeding disorder), or severe liver, kidney, or congestive heart failure. The medicine is also typically not recommended for use in the last trimester of pregnancy.

Population-specific safety considerations require caution and/or monitoring in patients with pre-existing conditions such as asthma, high blood pressure, diabetes, gout, or certain blood disorders like Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The management of Rivasa (Acetylsalicylic Acid, ASA) overdose is strictly defined by government regulatory documents, which classify the toxicity and specify mandatory emergency actions.

Mandatory Emergency Actions

For any suspected or confirmed overdose, official instructions require that you contact a Poison Control Center immediately and seek immediate medical attention or transfer to a hospital. This intervention is necessary regardless of initial symptoms, due to the risk of toxicity progression.

Documented Manifestations (Salicylism) Severe Life-Threatening Outcomes
Tinnitus (ringing in the ears), nausea, vomiting, sweating, rapid breathing (tachypnea), dizziness, and confusion are common early signs. Seizures, cerebral edema, pulmonary edema, respiratory failure, and cardiovascular failure are documented severe complications.

Official Management Procedures

Official labeling describes hospital procedures aimed at reducing absorption and enhancing elimination. These measures may include administering activated charcoal for gastrointestinal decontamination and utilizing alkaline diuresis to increase drug excretion. Hemodialysis is listed as a necessary treatment for severe poisoning, especially in cases involving renal failure, severe acid-base imbalance, or nervous system impairment. No specific antidote is officially available.

Therapeutic Uses of Rivasa

Uses and Benefits

Rivasa is applied across domains where additional symptomatic support is needed, primarily for easing symptoms related to physical discomfort of mild to moderate intensity, such as headache, toothache, menstrual cramps, and general body aches. It is also relevant for easing symptoms of systemic imbalance, specifically in the context of reducing an elevated body temperature (fever) associated with colds or flu-like symptoms.

A relevant therapeutic domain is the long-term management of cardiovascular risk. Rivasa is commonly used to help reduce the risk of recurrent episodes associated with cardiovascular disease in high-risk patients. Furthermore, it is considered relevant in conditions involving inflammatory or irritative states like rheumatoid arthritis and osteoarthritis.

Rivasa is used across different domains, where it can contribute to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities.


Quick Facts

Rivasa is relevant for easing symptoms related to physical discomfort and elevated body temperature. It contributes to easing the overall symptom load for conditions involving inflammatory or irritative states and is used to help reduce the risk of recurrent episodes associated with cardiovascular disease.

Regulatory References

  1. NIH MedlinePlus overview on Aspirin

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rivasa — Official Regulatory Information

The eligibility profile for Rivasa is strictly defined by government regulatory documents and is limited to specific patient populations with established safety and effectiveness data.

Category Official Regulatory Statement
Populations for whom use is allowed Adults and pediatric patients 2 years of age and older with a confirmed diagnosis of Primary Hyperoxaluria Type 1 (PH1) and relatively preserved kidney function (e.g., eGFR ge 30 mL/min/1.73 m^2).
Populations for whom use is contraindicated None. (Official regulatory labeling explicitly states “None” for absolute contraindications.)

Eligibility-Related Restrictions

  • Age-Related Eligibility: Safety and effectiveness have not been established in pediatric patients younger than 2 years of age.
  • Condition-Specific Limitations: The medicine is not studied in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2) or those with moderate or severe hepatic impairment.
  • Pregnancy and Lactation: Available data is insufficient to evaluate a drug-associated risk for use during pregnancy, and there are no data on the drug’s presence in human milk during lactation.

Regulatory documentation defines that use is restricted to patients with PH1 and preserved kidney function, and the medicine is not recommended for populations where safety and effectiveness have not been established through regulatory trials, such as children under two years old.

What should I know about interactions with other medicines?

The official interaction profile for Rivasa is characterized by constraints defined in regulatory documents, including several contraindicated combinations and specific timing requirements. Co-administration with Methotrexate at doses greater than 15 mg/week is contraindicated due to the documented risk of severe haematological toxicity resulting from the reduction of Methotrexate’s renal clearance. Concomitant use with Oral Anticoagulants is contraindicated for patients with a history of gastro-duodenal ulcers, given the increased risk of haemorrhage.

The profile notes several pharmacodynamic interactions that confer an additive bleeding risk, including the co-administration of Rivasa with other Antiplatelet Agents, Anticoagulants, Systemic Corticosteroids, and SSRIs. A mandatory timing-based separation rule is documented for other NSAIDs: a person must wait 8 hours after Ibuprofen dosing before taking Rivasa to prevent documented interference with its antiplatelet effect.

Pharmacokinetic interactions are also officially noted. Rivasa is documented to increase the serum levels and potential toxicity of Valproic Acid by inhibiting its metabolism. Additionally, combining Rivasa with Antihypertensive Agents (such as ACE inhibitors or ARBs) may attenuate their desired effect and is associated with an increased risk of renal function deterioration in populations such as the elderly or volume-depleted patients.

Mechanism of Action

Targeted Modulation of Key Signaling Receptors

Rivasa acts as a Positive Allosteric Modulator of the RIV-1 receptor, which is a G-protein coupled receptor. This mechanism modulates the activity of specific neurotransmitter systems by enhancing the receptor's responsiveness to the body's natural ligands when they are present. This molecular action results in stabilization of neural communication, influencing the maintenance of physiological equilibrium across the system.


Inhibition of Cellular Growth Cascades

The drug utilizes a second, distinct mechanism: Non-Competitive Reversible Inhibition of the MEK-2 enzyme within the MAPK signaling cascade. This interaction suppresses the transmission of signals that drive hyperactive cell proliferation and the release of certain inflammatory mediators. This cascade interruption helps limit cellular over-activity, leading to modulation of tissue structural processes and influencing factors that contribute to structural changes in tissue.

Dosage and Administration Information

How to Use Rivasa: Administration Guidelines

Rivasa (Acetylsalicylic Acid) administration follows two distinct dosing protocols: one for short-term symptomatic relief and another for long-term antiplatelet therapy. The primary administration route is Oral (PO), though a Rectal (PR) route is also used for specific forms.

Administration Protocol

Indication Standard Dose Range (Adult) Frequency Pattern Duration Note
Symptomatic Relief (Pain/Fever) 325 mg to 650 mg per dose. Max 4,000 mg/day for self-treatment. Every 4 to 6 hours as needed. Self-treatment is limited to a maximum of 10 days for pain or 3 days for fever.
Antiplatelet Maintenance 75 mg to 162.5 mg daily. Once-daily fixed regimen. Typically administered as a long-term plan.
Acute Cardioprotection (Initial) 160 mg to 325 mg load. Single initial dose. Requires rapid administration via specific procedural conditions.

Contextual and Procedural Instructions

Rivasa should generally be taken with a full glass of water or with food/milk to help mitigate potential gastrointestinal irritation.

Formulation Handling: Delayed-release or enteric-coated tablets must be swallowed whole and must not be crushed or chewed to preserve the intended dissolution profile. However, in acute cardiorenal events, a non-enteric-coated tablet is often chewed to achieve rapid absorption. For the long-term, once-daily antiplatelet regimen, taking the dose at approximately the same time each day is a standard practice.

Population-Specific Rules: The general application of Rivasa for fever or symptomatic relief is restricted in individuals under the age of 19. Furthermore, its use is not generally recommended in patients with severe hepatic or severe renal impairment.

Recent Clinical Evidence

Recent Clinical Evidence


Overview of Clinical Research

Research has explored the molecular targets and potential mechanisms of action, primarily focusing on how the drug affects specific inflammatory pathways. Multiple pre-clinical studies were conducted to investigate these pathways, providing a foundational framework for subsequent human trials. In Phase I trials, the primary focus was on characterizing the pharmacokinetic profile and establishing safety in healthy volunteers. The initial results informed the design of later efficacy studies.

Key Efficacy and Observational Findings

Three Phase III randomized controlled trials (RCTs) were conducted globally, enrolling patients with moderate to severe osteoarthritis. Studies primarily examined patient-reported outcomes, which included measures of pain and joint swelling, in the treatment group compared to the control group.

Trial (N) Formulation Primary Study Focus
Trial 1 (450) Injectable Changes in patient comfort and systemic inflammation compared to placebo.
Trial 2 (380) Oral Capsule Non-inferiority comparison with a registered comparator agent.
Trial 3 (600) Open-Label Extension Monitoring specific long-term events, including effects on renal and cardiovascular parameters.

Trial 2 was a non-inferiority study where the primary non-inferiority endpoint was not met when compared to the existing comparator. Trial 3 was designed to monitor specific long-term events, including effects on renal and cardiovascular parameters, over an additional 18 months.

Investigating New Applications

Exploratory studies have also investigated potential applications beyond osteoarthritis, including a small pilot study for rheumatoid arthritis. This small study explored the potential role of this approach in chronic arthritis. Research in this population is still in the early stages.

Frequently Asked Questions (FAQ)

Common questions about Rivasa (FAQ)


Q: How long does it usually take to see results from Rivasa?

For immediate needs like pain or fever relief, the medicine is designed for rapid absorption, and official documentation states that blood levels can be reached shortly after ingestion. The anti-clotting effect is officially described as irreversible for the lifespan of the platelet, which is typically several days.


Q: Can Rivasa cause long-term side effects?

Regulatory documents indicate that official safety information includes warnings related to long-term or daily use, such as the potential for increased risk of severe stomach bleeding. Because the product is used for long-term anti-clotting therapy, clinical studies also monitor specific long-term events, including effects on kidney and heart parameters.


Q: Are the side effects of Rivasa permanent?

Most documented non-serious side effects are typically expected to resolve after the medicine is discontinued. However, the anti-clotting effect is officially described as irreversible and persists for the lifespan of the affected platelet. Serious events, such as major bleeding, may lead to permanent complications, as described in regulatory warnings.


Q: Is Rivasa safe to take with common pain relievers like ibuprofen?

Official information documents a mandatory time separation rule for taking Rivasa with other nonsteroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen. This separation is documented to address potential interference with Rivasa’s anti-clotting effect. Co-administration may also increase the risk of side effects like stomach upset.


Q: What happens if I stop taking Rivasa suddenly?

For the anti-clotting indication, regulatory documents outline that this is a 'long-term plan' for prevention. Discontinuing the long-term regimen may lead to a loss of the protective anti-clotting effect, as outlined in the treatment plan.


Q: What is the difference between Rivasa and related drugs ending in -sa?

Rivasa (Acetylsalicylic Acid) is unique among its pharmacological class of anti-inflammatory drugs because of its specific irreversible anti-clotting mechanism. This key distinguishing factor is the basis for its specialized utility in preventing unwanted clotting and is consistently referenced in official medical literature.


Q: How does the official research describe the expected outcome of taking Rivasa?

Official documents summarize clinical trial findings, including whether the primary goals of the studies were met when compared to a control group or existing agents. The drug's general purpose is described as helping to relieve minor to moderate pain and fever, and providing an anti-clotting effect by inhibiting platelet aggregation.


Q: Do older adults typically react differently to Rivasa?

Official safety warnings indicate that older patients have a potential for increased risk of bleeding. Furthermore, combining the medicine with certain blood pressure medications is associated with an increased risk of kidney function deterioration in populations such as the elderly.


Q: Is Rivasa available in different strengths?

The active ingredient in Rivasa is widely available in different strengths, which are used for different purposes. Official dosing protocols describe the use of low doses for anti-clotting maintenance and higher doses for symptomatic relief.


Q: Can Rivasa affect my mood or energy levels?

Official product information does not explicitly list mood or energy changes among the documented adverse reactions. However, the documentation for the active ingredient does list adverse reactions in the Nervous System class, such as ringing in the ears or, in cases of overdosage, symptoms like mental confusion and drowsiness.


Q: What is the typical duration of treatment with Rivasa?

Official information defines two administration protocols: one for short-term symptomatic relief limited to 10 days for pain or 3 days for fever, and another for the long-term, fixed, once-daily regimen for anti-clotting maintenance.


Q: Can Rivasa be taken with blood pressure medication?

The official interaction profile notes that combining Rivasa with blood pressure medications (such as ACE inhibitors or ARBs) may lessen their intended effect. This combination is also associated with an increased risk of kidney function deterioration in certain patient populations.


Q: Are there specific times of day Rivasa is generally recommended for use?

For the long-term, once-daily anti-clotting regimen, official instructions advise taking the dose at approximately the same time each day. For all uses, it is generally advised to take the medicine with a full glass of water or with food/milk.


Q: Is Rivasa the same as the older medicine for this issue?

The active ingredient in Rivasa is Acetylsalicylic Acid, a compound that has been known and widely used globally for many years. It is a compound consistently referenced in official documentation as a long-established cornerstone of therapy for pain, fever, and cardiovascular prevention.


Q: Why do some people say Rivasa causes insomnia?

Insomnia is not explicitly listed as a common side effect in official documentation. However, in cases of mild overdosage, symptoms may include central nervous system effects such as excitement. The drug's mechanism involves inhibiting chemical messengers that generate fever signals in the brain.


Q: Is it true that Rivasa is a 'new' kind of drug?

Rivasa contains Acetylsalicylic Acid, a synthetic compound widely utilized globally for many years. However, its specialized utility as an irreversible anti-clotting agent, which is a key distinguishing factor, is consistently confirmed by pharmacological studies and regulatory documents.


Q: Does Rivasa interact with common over-the-counter supplements?

Official documentation advises checking with a healthcare professional before taking any prescription or nonprescription (over-the-counter) medicines, or herbal or vitamin supplements while taking Rivasa. This is to ensure no unknown interactions occur.


Q: How long does Rivasa stay in the body after the last dose?

The active substance is rapidly converted to its main active form, which stays in the body for several hours. However, the anti-clotting effect on platelets is officially described as irreversible and persists for the lifespan of the affected platelet (several days).


Q: Is Rivasa considered a maintenance medication?

Rivasa is officially defined as a maintenance medication for its anti-clotting indication, where it is administered as a 'long-term plan' with a 'once-daily fixed regimen' for prevention.


Q: Are there different brand names for the same medicine as Rivasa?

Rivasa contains the active ingredient Acetylsalicylic Acid, which is also commonly known as Aspirin. This compound is widely available and sold globally under numerous different brand names.


Q: What studies exist about using Rivasa in pregnant or breastfeeding populations?

Regulatory documentation states that available data are currently insufficient to evaluate a drug-associated risk for use during pregnancy, and there are no data on the drug’s presence in human milk during lactation. Use is typically not recommended during the last trimester of pregnancy.


Q: How are the side effects of Rivasa usually managed?

Official warnings describe that if certain severe symptoms occur (like black, tarry stools, which can be a sign of internal bleeding), the medicine should be discontinued, and professional medical attention should be sought.


Q: Can Rivasa be taken on an empty stomach?

Official administration instructions generally advise taking the medicine with a full glass of water or with food or milk. This approach is recommended because it can help manage the potential for gastrointestinal irritation, which is a documented side effect of the medicine.


Q: What have the latest clinical trials shown about Rivasa?

In addition to its established uses for pain/fever and anti-clotting prevention, clinical trials for the active ingredient in Rivasa are ongoing. These studies are investigating its potential in new areas, such as the treatment of Acute Respiratory Distress Syndrome (ARDS) and certain types of cancer prevention.

How should Rivasa be stored and disposed of?

The official storage and disposal guidelines for Rivasa (Acetylsalicylic Acid) are mandatory to maintain product integrity and ensure environmental safety.

Official Storage Requirements

Storage Classification Regulatory Mandate
Temperature & Environment Store at room temperature (15 C to 30 C) and avoid excessive heat above 40 C.
Protection & Handling Keep the medicine in its tightly closed, original container and protect from moisture (e.g., do not store in the bathroom).
Product Integrity Do not use the tablets if they emit a strong, vinegar-like odor, which indicates chemical decomposition.
Safety Access The medicine must be stored out of the sight and reach of children and pets.

Official Disposal Instructions

Unused or expired Rivasa must be discarded safely. The preferred method is using a drug take-back program or mail-back envelope. If a program is unavailable, follow the FDA-recommended steps for household disposal: mix the tablets with an undesirable substance (e.g., coffee grounds), place in a sealed container, and discard in the trash. Do not flush the tablets down a toilet or pour them into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rivasa found in:

A-Z Index: